Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 326359, 7 pages
http://dx.doi.org/10.1155/2015/326359
Research Article

Effects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15

1Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 16143 Genoa, Italy
2Division of Cardiology, Department of Medicine, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, 64 Avenue de la Roseraie, 1211 Geneva, Switzerland
3Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland

Received 10 December 2014; Accepted 17 June 2015

Academic Editor: Ike S. Okosun

Copyright © 2015 Alessandra Puddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Creutzfeldt, “The incretin concept today,” Diabetologia, vol. 16, no. 2, pp. 75–85, 1979. View at Publisher · View at Google Scholar · View at Scopus
  2. W. Creutzfeldt and R. Ebert, “New developments in the incretin concept,” Diabetologia, vol. 28, no. 8, pp. 565–573, 1985. View at Google Scholar · View at Scopus
  3. J. J. Meier and M. A. Nauck, “Glucagon-like peptide 1(GLP-1) in biology and pathology,” Diabetes/Metabolism Research and Reviews, vol. 21, no. 2, pp. 91–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. Nauck, E. Bartels, C. Orskov, R. Ebert, and W. Creutzfeldt, “Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 4, pp. 912–917, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Nauck, E. Homberger, E. G. Siegel et al., “Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses,” The Journal of Clinical Endocrinology & Metabolism, vol. 63, no. 2, pp. 492–498, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. L. T. Shuster, V. L. W. Go, R. A. Rizza, P. C. O'Brien, and F. J. Service, “Incretin effect due to increased secretion and decreased clearance of insulin in normal humans,” Diabetes, vol. 37, no. 2, pp. 200–203, 1988. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt, “Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes,” Diabetologia, vol. 29, no. 1, pp. 46–52, 1986. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Nauck, M. M. Heimesaat, C. Orskov, J. J. Holst, R. Ebert, and W. Creutzfeldt, “Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type- 2 diabetes mellitus,” The Journal of Clinical Investigation, vol. 91, no. 1, pp. 301–307, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. J. J. Meier, K. Hücking, J. J. Holst, C. F. Deacon, W. H. Schmiegel, and M. A. Nauck, “Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes,” Diabetes, vol. 50, no. 7–12, pp. 2497–2504, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. L. L. Kjems, J. J. Holst, A. Vølund, and S. Madsbad, “The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects,” Diabetes, vol. 52, no. 2, pp. 380–386, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. J. Meier, M. A. Nauck, W. E. Schmidt, and B. Gallwitz, “Gastric inhibitory polypeptide: the neglected incretin revisited,” Regulatory Peptides, vol. 107, no. 1–3, pp. 1–13, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. J. J. Holst, J. Gromada, and M. A. Nauck, “The pathogenesis of NIDDM involves a defective expression of the GIP receptor,” Diabetologia, vol. 40, no. 8, pp. 984–986, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. C.-C. Tseng, M. O. Boylan, L. A. Jarboe, T. B. Usdin, and M. Michael Wolfe, “Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 270, no. 4, pp. E661–E666, 1996. View at Google Scholar · View at Scopus
  15. J. J. Meier and M. A. Nauck, “Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 18, no. 4, pp. 587–606, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. F. C. Lynn, N. Pamir, E. H. C. Ng, C. H. S. McIntosh, T. J. Kieffer, and R. A. Pederson, “Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats,” Diabetes, vol. 50, no. 5, pp. 1004–1011, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. F. C. Lynn, S. A. Thompson, J. A. Pospisilik et al., “A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells,” The FASEB Journal, vol. 17, no. 1, pp. 91–93, 2003. View at Google Scholar · View at Scopus
  18. G. Xu, H. Kaneto, D. R. Laybutt et al., “Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes,” Diabetes, vol. 56, no. 6, pp. 1551–1558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Singh, A. Barden, T. Mori, and L. Beilin, “Advanced glycation end-products: a review,” Diabetologia, vol. 44, no. 2, pp. 129–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Jakuš and N. Rietbrock, “Advanced glycation end-products and the progress of diabetic vascular complications,” Physiological Research, vol. 53, no. 2, pp. 131–142, 2004. View at Google Scholar · View at Scopus
  21. G. Luciano Viviani, A. Puddu, G. Sacchi et al., “Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro,” Metabolism: Clinical and Experimental, vol. 57, no. 2, pp. 163–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Puddu, D. Storace, A. Durante, P. Odetti, and G. L. Viviani, “Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15,” Biochemical and Biophysical Research Communications, vol. 398, no. 3, pp. 462–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Puddu, D. Storace, P. Odetti, and G. L. Viviani, “Advanced glycation end-products affect transcription factors regulating insulin gene expression,” Biochemical and Biophysical Research Communications, vol. 395, no. 1, pp. 122–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Puddu, R. Sanguineti, F. Montecucco, and G. L. Viviani, “Glucagon-like peptide-1 secreting cell function as well as production of inflammatory reactive oxygen species is differently regulated by glycated serum and high levels of glucose,” Mediators of Inflammation, vol. 2014, Article ID 923120, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Sugiyama, T. Miyata, Y. Ueda et al., “Plasma levels of pentosidine in diabetic patients: an advanced glycation end product,” Journal of the American Society of Nephrology, vol. 9, no. 9, pp. 1681–1688, 1998. View at Google Scholar · View at Scopus
  26. M. Kerkeni, A. Saïdi, H. Bouzidi, A. Letaief, S. Ben Yahia, and M. Hammami, “Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients,” Diabetes and Vascular Disease Research, vol. 10, no. 3, pp. 239–245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Izuhara, T. Miyata, Y. Ueda et al., “A sensitive and specific ELISA for plasma pentosidine,” Nephrology Dialysis Transplantation, vol. 14, no. 3, pp. 576–580, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. S. G. Straub and G. W. G. Sharp, “Glucose-dependent insulinotropic polypeptide stimulates insulin secretion via increased cyclic AMP and [Ca2+]i and a Wortmannin-sensitive signalling pathway,” Biochemical and Biophysical Research Communications, vol. 224, no. 2, pp. 369–374, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. S. J. Kim, K. Winter, C. Nian, M. Tsuneoka, Y. Koda, and C. H. McIntosh, “Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression,” Journal of Biological Chemistry, vol. 280, no. 23, pp. 22297–22307, 2005. View at Publisher · View at Google Scholar
  30. A. Trümper, K. Trümper, H. Trusheim, R. Arnold, B. Göke, and D. Hörsch, “Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling,” Molecular Endocrinology, vol. 15, no. 9, pp. 1559–1570, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Trümper, K. Trümper, and D. Hörsch, “Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells,” Journal of Endocrinology, vol. 174, no. 2, pp. 233–246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Moens, H. Heimberg, D. Flamez et al., “Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells,” Diabetes, vol. 45, no. 2, pp. 257–261, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Kim and J. M. Egan, “The role of incretins in glucose homeostasis and diabetes treatment,” Pharmacological Reviews, vol. 60, no. 4, pp. 470–512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. B. M. T. Burgering and P. J. Coffer, “Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction,” Nature, vol. 376, no. 6541, pp. 599–602, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Piteau, A. Olver, S.-J. Kim et al., “Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat,” Biochemical and Biophysical Research Communications, vol. 362, no. 4, pp. 1007–1012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Ceriello, M. A. Ihnat, and J. E. Thorpe, “The ‘Metabolic memory’: is more than just tight glucose control necessary to prevent diabetic complications?” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 2, pp. 410–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Drzewoski, J. Kasznicki, and Z. Trojanowski, “The role of ‘metabolic memory’ in the natural history of diabetes mellitus,” Polskie Archiwum Medycyny Wewnetrznej, vol. 119, no. 7-8, pp. 493–500, 2009. View at Google Scholar · View at Scopus
  38. S. Roy, R. Sala, E. Cagliero, and M. Lorenzi, “Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 1, pp. 404–408, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. J. J. Meier and M. A. Nauck, “Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?” Diabetes, vol. 59, no. 5, pp. 1117–1125, 2010. View at Publisher · View at Google Scholar · View at Scopus